AstraZeneca's 3-in-1 inhaler helps COPD patients in trial

(Reuters) - AstraZeneca said an inhaler for chronic obstructive pulmonary disease (COPD) delivered improved lung function in a late stage trial that could challenge GlaxoSmithKline's new three-in-one inhaler.